VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒══════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                    │   Score │
╞══════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Adult Patients with Overt Hepatic Encephalopathy │ Adult Patients with Overt Hepatic Encephalopathy │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients with active GIT bleeding                │ Patients with active GIT bleeding                │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients with history of bowel obstruction,      │ Patients with history of bowel obstruction,      │     100 │
│ perforation                                      │ perforation                                      │         │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients with history of allergy to PEG          │ Patients with history of allergy to PEG          │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Treatment with rifaximin or neomycin in the      │ Treatment with rifaximin or neomycin in the      │     100 │
│ previous 7 days                                  │ previous 7 days                                  │         │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients with major psychiatric illness          │ Patients with major psychiatric illness          │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients receiving benzodiazepines and narcotics │ Patients receiving benzodiazepines and narcotics │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients with compromised renal                  │ Patients with compromised renal                  │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients receiving medications highly bound to   │ Patients receiving medications highly bound to   │     100 │
│ plasma proteins eg. Warfarin                     │ plasma proteins eg. Warfarin                     │         │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women                      │ Pregnant or lactating women                      │     100 │
├──────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Fulminant hepatic failure                        │ Fulminant hepatic failure                        │     100 │
╘══════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Your personal trial has no unique criteria

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 100.0
OverAll Ratio: 100.0
